Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
July 2012, Vol 3, No 5
July 2012, Vol 3, No 5
Unforeseen Hospital Admissions Are Frequent for Patients Receiving Radiotherapy
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Approximately 1 in 5 patients with cancer who are undergoing radiotherapy as part of their treatment can count on unexpected hospital stays—adding an economic and clinical burden on the patient and on the healthcare system, according to an analysis by Nabeel H. Arastu, BS, and colleagues at the Brody School of Medicine at East Carolina University, Greenville, NC, which was presented at the 2012 ASCO meeting.
Read Article
ODAC Recommends Carfilzomib for Myeloma
FDA Approvals, News & Updates
July 2012, Vol 3, No 5
The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended in an 11 to 0 vote (and 1 absentee) to approve carfilzomib (Kyprolis; Onyx), a new-generation proteasome inhibitor, for the treatment of patients with refractory and relapsed multiple myeloma who have failed at least 2 other myeloma therapies—the proteasome inhibitor bortezomib (Velcade) and the immunomodulatory drug lenalidomide (Revlimid).
Read Article
New Test for Aiding Biopsy Decision after PSA Test
FDA Approvals, News & Updates
July 2012, Vol 3, No 5
The US Food and Drug Administration (FDA) has approved the Access Hybritech p2PSA (Beckman Coulter) test, which measures a form of prostate-specific antigen (PSA) called [-2]proPSA in the blood and can help men whose PSA test scores are elevated decide whether they should have a biopsy to rule out prostate cancer.
Read Article
Researchers Highlight Benefits of Exercise for Patients with Cancer
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
Several researchers at the University of Rochester Medical Center have been studying the effects of exercise on patients with cancer for some time now.
Read Article
First US Hospital Integrates Psychosocial Support Services in Its Cancer Center
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
Greenville Hospital System (GHS) has launched the Center for Integrative Oncology and Survivorship, which offers emotional services for cancer survivors developed by Cancer Support Community (CSC), an international provider of cancer-related social and emotional services.
Read Article
World’s First Pediatric Lymphoma Research Center Launched
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
Texas Children’s Cancer Center has opened the first center dedicated entirely to the research, care, and treatment of children with lymphoma. The Fayez Sarofim Lymphoma Center at Texas Children’s Cancer Center was made possible by a gift of $10 million to Texas Children’s Hospital.
Read Article
New Biomarker a Promising Development in Ewing’s Sarcoma
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
A team of researchers from the University of Colorado led by Tyler Robin, PhD, Department of OB/GYN, Denver Anschutz Medical Campus, has discovered a new biomarker in Ewing’s sarcoma that explains the lack of disease response to current chemotherapy in some patients with this cancer, who until now have had a very poor prognosis.
Read Article
Precision Diagnostics Currently the True Value of Personalized Medicine
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
>According to Genome Health Solutions cofounder Mark S. Boguski, MD, PhD, FCAP, Harvard Medical School’s Center for Biomedical Informatics and Beth Israel Deaconess Medical Center, at this point in time, the promise of genomics lies “not so much in therapeutics or disease prevention, but in precision diagnostics that will really enable personalized medicine.
Read Article
Anti–PD-1/PD-L1 Antibodies Show Promising Antitumor Activity in Several Cancers
In the Literature
July 2012, Vol 3, No 5
Results from two phase 1 clinical trials—one evaluating an anti–PD-1 antibody (Topalian SL, et al.
N Engl J Med
. 2012; 366:2443-2454) and the second evaluating an anti–PD-1 ligand (PD-L1) antibody (Brahmer JR, et al.
N Engl J Med
. 2012;366:2455-2465)—suggest that targeting the PD-1/PD-L1 pathway may be beneficial in treating certain types of solid tumors, including advanced melanoma, non–small-cell lung cancer (NSCLC), and renal-cell cancer.
Read Article
Regorafenib Active in Advanced GIST after Failing Standard Therapy
In the Literature
July 2012, Vol 3, No 5
New data suggest that regorafenib, a unique inhibitor of several kinase-associated cancers, has a wide-range activity in this patient population (George S, et al.
J Clin Oncol
. 2012;30:2401-2407).
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma